Giampaolo Bianchini
@BianchiniGP
Followers
3K
Following
8K
Media
77
Statuses
3K
Head Breast Cancer Group; Head translational and immunotherapy research group; San Raffaele Scientific Institute, Milan, Italy; #PrecisionImmunology
Milano, Lombardia
Joined July 2021
📢1/10 Out on @Nature our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ lead by @HRazaAliLab and myself.👉To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context.🧵👇
18
103
362
RT @MariosGeorgakis: I read this Cell paper that argues to have discovered a molecule (betaine) that mimics the geroprotective effects of e….
0
139
0
RT @f_rossari: 🧵1/.🚨 Just out in Science Translational Medicine @ScienceTM our latest work @NaldiniLab:.We show how tumor-targeted cytokine….
0
11
0
🔥 Primary tumor resection in Stage IV BC?. Overall, no OS benefit in JCOG1017 trial, but very interesting results. 👉 Huge benefit in local control.👉Metastatic BC is heterogeneous (e.g. oligometastatic, subtypes, treatments response) . Not for all, but an option for some?
JCOG1017 trial found that primary tumor resection (PTR) did not prolong overall survival in de novo Stage IV breast cancer. However, it improved local control and might benefit subsets like premenopausal patients or those with single-organ metastasis. @JGbreast @TADSHIEN
1
21
58
RT @kazuki_nozawa: JCOG1017 trial found that primary tumor resection (PTR) did not prolong overall survival in de novo Stage IV breast canc….
0
25
0
RT @curijoey: 🎉 Congratulazioni ad Antonio Marra per aver vinto il prestigioso grant Next Generation AIRC!.Un traguardo straordinario che l….
0
8
0
RT @PTarantinoMD: First positive phase 3 trial for a bispecific ADC (EGFR/HER3 topo1 ADC), co-developed by BiokinPharma & BMS. Bispecific A….
0
22
0
RT @jsoriamd: ctDNA/CTC-based liquid biopsies are redefining clinical oncology: enabling population screening, early relapse flagging, phar….
0
6
0
RT @jsoriamd: Great graphics and global overview on cancer prevalence and therapeutic improvements in this article. Overall cancer survival….
0
441
0
RT @MyriamChalabi: Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NS….
0
61
0
RT @medoncodoc: A nice review on Postmastectomy RT and RNI in the era of de-escalation of treatment .#bcsm . @Erika….
0
23
0
RT @VivekSubbiah: 🚨When a Phase 1 trial in any field lands in @NEJM, you know it’s “extraordinary” .🧬 Stem cell–derived islets for Type1 Di….
0
17
0
0
14
0
RT @tompowles1: Thanks to the whole @Annals_Oncology team, @FAndreMD & all the authors for driving up the quality of the journal (IF64)….
0
9
0
RT @medoncodoc: 🔥 Breakthrough in HR+HER2– Breast Cancer!. 🧬 In I-SPY2 trial (n=395), ImPrint, an mRNA-based immune classifier, predicted r….
0
12
0
RT @PTarantinoMD: Great questions. We conducted a separate analysis of outcomes post-T-DXd by MBC subtype, presented at #SABCS24 and curren….
0
28
0
RT @mirrorsmed: Overcoming resistance to CDK4/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: Innovative combinatio….
0
9
0